Please assess the completion status of the following clinical trial:

Trial Title: Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age \>18 years~* Histologically confirmed and centrally reviewed prostate adenocarcinoma based~* PSA within 60 days~* High risk prostate cancer defined as any one of: clinical stage \>= T3, Gleason score \>= 8, or PSA \>=20 and \<50 ng/mL.~Exclusion Criteria:~* Evidence of lymph node metastasis~* Evidence of distant metastases~* Prior pelvic radiotherapy or brachytherapy~* Previous radical prostatectomy, cryotherapy, or high-frequency ultrasound~* Unable to undergo gold seed insertion~* Immunosuppressive medications~* Inflammatory bowel disease~* Unable to undergo MRI~* Previous bilateral orchiectomy~* Previous hormonal therapy including LHRH agonists (leuprolide, goserelin), LHRH antagonists (degarelix), anti-androgens (bicalutamide, flutamide, nilutamide), surgical castration, and estrogens~* Previous finasteride within 14 days.~* Previous dutasteride within 180 days.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostate stereotactic body RT with MR-guided boost (Type: EXPERIMENTAL): Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.

Based on this trial design, predict the completion outcome and termination type (if applicable).